News
Events
Publications
News
VahatiCor Enrolls First U.S. Patient in SERRA-I Clinical Study of A-FLUX Reducer System® for CMD
The milestone builds on early human experience from SERRA-I and ongoing enrollment in the SERRA-I European (EU) study.
VahatiCor Appoints Harry D. Rowland, Ph.D., as Chief Executive Officer
Endotronix co-founder and former CEO joins VahatiCor as the company advances the A-FLUX Reducer System® and the SERRA-I early feasibility study
VahatiCor Closes Oversubscribed Series B Financing to Accelerate A-FLUX® Development for Coronary Microvascular Dysfunction.
The new capital will advance the SERRA-I early feasibility study, engineering development, and preparation for additional studies on coronary microvascular dysfunction.
VahatiCor Reports Positive Results From Its A-FLUX Reducer System® Compassionate Use Cases
VahatiCor, a leader in cardiovascular innovation, is proud to announce the successful completion of its compassionate use study treating patients with the A-FLUX Reducer System™ for either obstructive coronary artery disease with persistent symptoms or symptomatic coronary microvascular dysfunction (CMD).
ORBITA-COSMIC: Validating the Efficacy of Coronary Sinus Reducers
The ORBITA-COSMIC trial’s results have confirmed the symptomatic benefits of coronary sinus reducer therapy in treating angina. This second sham-controlled trial validates the effectiveness of reducer therapy and positions it for earlier treatment in the presence of riskier alternatives.
VahatiCor, Inc. Announces Treatment of the First Patient with the A-FLUX Reducer System®
VahatiCor, Inc., today announced the treatment of the first patient with the A-FLUX Reducer System, a treatment for patients with angina or chest pain. “We have many interventional or surgical revascularization options for patients with advanced large coronary artery disease. However, a significant proportion still suffer from angina. The A-FLUX Reducer could help to fill that therapeutic void. It was an honor to perform the first-in-human implant and the patient is doing great,” said Dr. Jean-Michel Paradis.
Events
Coronary Microvascular Dysfunction in the Spotlight at EuroPCR 2026
This year at EuroPCR, we filled the symposium room yet again, and the conversation around Coronary Microvascular Dysfunction is taking shape. The smallest vessels matter. Micro is Huge.
Spotlight on Coronary Microvascular Dysfunction at TCT 2025
For the second time this year, we’ve organized a scientific symposium at a major interventional cardiology conference. We’ve put together an excellent panel to dive deep into Coronary Microvascular Dysfunction.
Coronary Microvascular Dysfunction in the Spotlight at EuroPCR 2025
Thank you to everyone who filled the room and the overflow space outside for this year’s EuroPCR symposium. The turnout alone speaks volumes about the growing urgency of better diagnosing and treating CMD.
Publications
VahatiCor Completes Compassionate Use Study of A-FLUX Reducer System®
Cardiac Interventions Today
November 11, 2024
A-FLUX®: a novel self-expanding coronary sinus reducer for refractory angina
Euro Intervention
Aug 5, 2024